

MOL #56192

Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen

John F. Deeken, Robert W. Robey, Suneet Shukla, Kenneth Steadman, Arup Chakraborty,
Balasubramanian Poonkuzhali, Erin G. Schuetz, Susan Holbeck, Suresh V. Ambudkar, and
Susan E. Bates.

Authors' affiliations: Lombardi Comprehensive Cancer Center, Georgetown University
Medical Center, Washington, D.C. USA (J.F.D., K.S); Medical Oncology Branch (R.W.R.,
A.C., S.E.B.) and Laboratory of Cell Biology (S.S., S.V.A.), Center for Cancer Research,
National Cancer Institute, Bethesda, MD, USA; Department of Hematology, Christian Medical
College, Vellore, India (B.P.); Department of Pharmaceutical Sciences, St. Jude Children's
Research Hospital, Memphis, TN, USA (E.G.S.); Developmental Therapeutics Program,
National Cancer Institute, Bethesda, MD, USA (S.H.).

MOL #56192

Running title: *ABCG2 in the NCI Anticancer Drug Screen*

Correspondence: John F. Deeken, M.D. Lombardi Comprehensive Cancer Center,
Georgetown University Medical Center, 3800 Reservoir Road, N.W., Washington, D.C. 20007,
USA; E-mail: deekenj@georgetown.edu; Tel: +1 (202) 444-3959; Fax: +1 (202) 444-9429.

Text pages: 35

Tables: 4

Figures: 4

References: 38

Abstract Word Count: 247

Introduction Word Count: 750

Discussion Word Count: 1356

Abbreviations:

P-gp: P-glycoprotein; MRP1: multidrug resistance-associated protein 1; ABC: ATP-binding cassette; FTC: Fumitremorgin C; PhA: pheophorbide a; IAAP: iodoarylazidoprazosin; PCC: Pearson correlation coefficient; SNP: single nucleotide polymorphism

MOL #56192

ABSTRACT

ABCG2 is an ATP-binding cassette transporter that counts multiple anticancer compounds among its substrates and is believed to regulate oral bioavailability as well as serve a protective role in the blood-brain barrier, the maternal-fetal barrier, and hematopoietic stem cells. We asked whether novel compounds that interact with the transporter could be identified through analysis of cytotoxicity profiles recorded in the NCI Anticancer Drug Screen database. A flow cytometric assay was used to measure ABCG2 function in the 60 cell lines and generate a molecular profile for COMPARE analysis. This strategy identified >70 compounds with Pearson correlation coefficients (PCCs) >0.4 where reduced drug sensitivity correlated with ABCG2 expression as well as >120 compounds with PCCs < -0.4, indicating compounds to which ABCG2 expression conferred greater sensitivity. Despite identification of known SNPs in the *ABCG2* gene in a number of the cell lines, omission of these lines from the COMPARE analysis did not affect PCCs. Available compounds were subjected to validation studies to confirm interaction with the transporter including flow cytometry, [¹²⁵I]-IAAP binding, and cytotoxicity assays and interaction was documented in 20 of the 27 compounds studied. Although known substrates of ABCG2 such as mitoxantrone or topotecan were not identified, we characterized 3 novel substrates – NSC 107392, 265473 and 349156 (pancratistatin) -- and four compounds that inhibited transporter function – NSC 24048, 45384, 103054, 636795. In summary, COMPARE analysis of the NCI drug screen database using the ABCG2 functional profile was able to identify novel substrates and transporter-interacting compounds.

MOL #56192

INTRODUCTION

ABCG2 is an ATP-binding cassette (ABC) half-transporter that has been linked to chemotherapeutic drug resistance. ABCG2 is highly expressed in a variety of normal tissues, including the endothelium in the central nervous system and the placenta as well as the small intestine, liver, and bile canniculi (Fetsch et al., 2005; Maliepaard et al., 2001). These expression levels and localizations highlight ABCG2's likely role in contributing to the blood-brain barrier, maternal-fetal barrier, and blood-germ cell barrier, as well as its role in the absorption and efflux of xenobiotics (Deeken and Loscher, 2007; Hardwick et al., 2007; Robey et al., 2007). Additionally, ABCG2 is highly expressed in a number of cancers including lung, endometrial, and gastrointestinal malignancies (Robey et al., 2007). Several studies have pointed to a role for ABCG2 in drug resistance in acute myelogenous leukemia (Benderra et al., 2004; Suvannasankha et al., 2004).

A number of chemotherapy agents are substrates for the transporter, including mitoxantrone, topotecan, irinotecan and its active metabolite SN-38, methotrexate, flavopiridol and some tyrosine kinase inhibitors (Hardwick et al., 2007; Robey et al., 2007). Several compounds have also been reported to act as inhibitors of ABCG2, including Fumitremorgin C (FTC) (Rabindran et al., 1998); the P-glycoprotein inhibitors elacridar (GF 120918) (de Bruin et al., 1999), tariquidar (XR9576) (Robey et al., 2004) and VX-710 (Minderman et al., 2004); and the tyrosine kinase inhibitors imatinib, nilotinib and gefitinib (Robey et al., 2007). ABCG2 inhibitors have potential uses in increasing oral bioavailability or CNS penetration of substrate drugs, potentially leading to more effective cancer treatments.

Somatic single nucleotide polymorphisms, or SNPs, have been discovered in the *ABCG2* gene (Honjo et al., 2002; Zamber et al., 2003). One non-synonymous substitution, 421C>A

MOL #56192

(dbSNP 914C>A, rs2231142), leads to an amino acid substitution of lysine for glutamine at position 141, and has been shown to result in lower plasma membrane expression, reduced drug efflux, and reduced ATPase activity (Imai et al., 2002; Mizuarai et al., 2004; Morisaki et al., 2005). The SNP also has been found to correlate with higher drug levels *in vivo* in patients exposed to chemotherapy drugs (Hardwick et al., 2007; Robey et al., 2007). This allelic variant has a broad range in frequency across different ethnic populations, with low frequency in African-Americans (2-5%), moderate frequency in people of European (11-14%), Hispanic (10%), and Middle Eastern (13%) descent, and high frequency in people of Chinese (35%) and Japanese (35%) descent (Lepper et al., 2005). While other SNPs within the *ABCG2* gene have not been found to correlate with a change in function or pharmacokinetics *in vivo*, recently Rudin correlated a SNP within the first intron of the gene (rs2282622) with increased toxicity in patients treated with erlotinib (Rudin et al., 2008).

The National Cancer Institute Developmental Therapeutics Program's Anticancer Drug Screen (NCI-ADS) has been used successfully over the past two decades to identify and classify new cancer therapies. Cytotoxicity assays have been performed on over 140,000 compounds against a set of 60 cell lines from various malignancies. The COMPARE program is a web-based tool configured to calculate pair-wise correlations between these cytotoxicity patterns, or 'fingerprints,' and other profiles, whether they be other cytotoxicity profiles or expression profiles of molecular targets within the cell lines. Targets such as EGFR, erbB2, p53 and Chk2 have been studied using this tool (Jobson et al., 2007; Liu et al., 2007; O'Connor et al., 1997; Wosikowski et al., 1997). This method has also been used in the past to study ABC transporters. Both expression and function profiles of P-gp were used to identify P-gp substrates and inhibitors through correlating cytotoxicity patterns with the P-gp data (Alvarez et al., 1995; Lee

MOL #56192

et al., 1994). Similarly, expression and function of MRP1 was also used to probe the NCI-ADS for possible transporter substrates (Alvarez et al., 1998). In contrast to P-glycoprotein, MRP1 expression and function was a poor predictor of MRP1 substrates or inhibitors (Alvarez et al., 1998).

ABCG2 mRNA expression in the 60 cell lines has previously been measured and used as the seed for a COMPARE analysis; however, a significant correlation between *ABCG2* expression and patterns of drug sensitivity did not emerge (Szakacs et al., 2004) and no substrates or inhibitors of *ABCG2* were identified. In this study, we used an assay based on pheophorbide a efflux that measured *ABCG2* transporter activity and thereby, expression. The functional data were used as the seed in a COMPARE analysis to investigate possible correlations with the drug sensitivity and resistance patterns of compounds contained in the NCI-ADS.

MATERIALS AND METHODS

Materials

Compounds used for this study were obtained through the Developmental Therapeutics Program of the National Cancer Institute (Bethesda, MD). Pheophorbide A (PhA) was obtained from Frontier Scientific (Logan, UT). Fumitremorgin C (FTC) was prepared by Thomas McCloud, Screening Technologies Branch of the National Cancer Institute's Developmental Therapeutics Program. Topotecan was purchased from LKT laboratories (St. Paul, MN). [¹²⁵I]-iodoarylazidoprazosin (IAAP) was obtained from Perkin Elmer Life Sciences (Wellesley, MA).

MOL #56192

Cell lines and cell culture

The cell lines of the NCI anticancer drug screen panel were obtained and grown in monolayers or in suspension in RPMI 1640 medium containing 10% fetal bovine serum, 2 mM glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin in 5% CO₂ at 37°. Human embryonic kidney cells (HEK-293, American Type Culture Collection, Manassas, VA) stably transfected with empty pcDNA 3.1 vector (Invitrogen, Carlstad, CA) (pcDNA) or vector containing full-length *ABCG2* were maintained in EMEM supplemented with 2 mg/ml G418 to enforce transporter expression (Robey et al., 2003). Validation studies also used *ABCG2*-overexpressing NCI-H460 MX20 cells that were obtained by step-wise selection and were maintained in 20 nM mitoxantrone (Robey et al., 2004). *ABCG2*-overexpressing MCF-7 FLV1000 cells were maintained in Richter's medium with 1000 nM flavopiridol (Robey et al., 2001). DNA isolated from the cell lines of the NCI drug screen were provided by the NCI Developmental Therapeutics Program.

ABCG2 Functional Assay

Functional assays with PhA were performed as previously described with minor modifications (Robey et al., 2004). Briefly, trypsinized cells were incubated for 30 minutes at 37°C in 1 µM PhA in the presence or absence of 10 µM of the *ABCG2* inhibitor FTC. The cells were subsequently washed and incubated at 37°C for one hour in PhA-free medium continuing with FTC to block *ABCG2*-mediated efflux of PhA and generate the FTC/efflux histogram (dashed line) or continuing without FTC during the 1 hr efflux period, generating the efflux histogram (solid line, see Figure 1A). PhA fluorescence was measured on a FACSort flow cytometer equipped with a 635-nm red diode laser. The difference in mean channel number

MOL #56192

between the FTC/efflux and efflux histogram, termed the inhibitable efflux, was calculated, and each cell line was tested at least twice. This value has been previously shown to correlate with ABCG2 expression (Robey et al., 2004). When the inhibitable efflux value was negative, it was assigned the value of zero.

This same method was used to test whether compounds identified in the NCI-ADS as potentially interacting with ABCG2 could inhibit transporter function. Potentially interacting compounds were incubated with wild-type ABCG2 transfected cells at a concentration of 10 μ M to determine whether they inhibited PhA efflux. Fold increase in PhA fluorescence was obtained by dividing the intracellular PhA fluorescence in the presence of each compound by the fluorescence in the absence of compound. Each compound was tested at least twice.

ABCG2 Expression Data

Measures of *ABCG2* gene expression were obtained from the NCI DTP. These results, obtained by polymerase chain reaction (Szakacs et al., 2004) and gene expression microarrays (Lee et al., 2003), are publicly available at http://dtp.nci.nih.gov/mtargets/mt_index.html. Seven measures of *ABCG2* mRNA were available and included in this study (NCI DTP identification numbers MT2678, GC14733, GC36729, GC56458, GC93477, GC152721 and GC228107).

ABCG2 SNP Genotyping

The NCI 60 cell lines were genotyped for variations in the *ABCG2* gene. After double stranded DNA content for each cell line was determined using the Quant-iT Picogreen dsDNA assay kit (Molecular Probes, Eugene, OR) in conjunction with a FLUOstar Optima (BMG Labtech, Durham, NC) fluorescence plate reader, the identification of single nucleotide

MOL #56192

polymorphisms (SNPs) was performed using two different methodologies. First, genotype identification for seven variant sites in the *ABCG2* gene were done for each cell line using the Affymetrix DMET platform as recently described (Dumauval et al., 2007). Second, genotyping for variations in intron 1 (rs2622604) was performed as follows: 20 ng genomic DNA was concentrated, applied, and dried to a 384 well thermoplate. Validated SNP identification primers for this variant along with VIC & FAM probes and master mix for the TaqMan SNP Genotyping Assay (Applied Biosystems, Foster City, CA) were added to the wells, then sealed and processed on a 7900HT Real Time PCR System (AME Bioscience, Torøed, Norway) for 40 Cycles (95°C for 15 seconds followed by 60°C for 60 seconds). SNP classification was performed with the onboard SDS 2.1 software and checked manually to ensure accuracy. The experiment was run in duplicate to confirm results.

National Cancer Institute Drug Screen database and COMPARE analysis

The National Cancer Institute Drug Screen database contains information on over 140,000 compounds characterized for cytotoxicity patterns in the 60 human cancer cell lines. Cytotoxicity curves are generated from which the 'GI₅₀' can be determined. The GI₅₀ is the time zero-corrected IC₅₀ value and is defined as the concentration of an agent that causes 50% growth inhibition. The GI₅₀ is different in each cell line, and the difference of that value from the mean GI₅₀ for the 60 cell lines for any given compound defines a cytotoxicity pattern which can be displayed as a "mean graph" or "fingerprint" (See Figure 4). A vertical line represents the mean response of the cell lines to the test agent. The COMPARE database stores the screening data as the -log(GI₅₀) for historical reasons related to the mean graph sign conventions (Lee et al., 1994). This means that data with higher IC₅₀s from more drug-resistant cell lines are stored with smaller

MOL #56192

(more negative) values and are found graphically to the left of the mean. Drug sensitive cell lines are graphed to the right. A profile or seed probe can be entered to query the database for compounds that have a high positive or negative correlation. We generated a fingerprint of ABCG2 function in the 60 cell lines of the drug screen and used this as a seed to obtain compounds that have cytotoxicity profiles correlating with the ABCG2 function profile. These compounds were then subjected to further testing.

Competition for [¹²⁵I]-IAAP labeling

Crude membranes (1 mg protein/ml) from the MCF-7 FLV1000 cells were incubated in 50 mM Tris-HCl (pH 7.5) containing 20 μM test compound or FTC for 10 min at room temperature. Subsequently, 3-6 nM [¹²⁵I]-IAAP (2200 Ci/mmol) was added and the samples were incubated for an additional 5 min under subdued light. The samples were illuminated with a UV lamp (365 nm) for 10 min at room temperature (21-23°C). Labeled ABCG2 was immunoprecipitated by adding 800 μL RIPA buffer with 1% aprotin followed by the addition of 10 μg of BXP-21 antibody (Kamiya Biomedical, Seattle, WA) after which the samples were incubated for 3h at 4°C. The beads were pelleted by centrifuging at 13,000 rpm for 5 min at 4°C and then washed with RIPA buffer in 1% aprotinin. SDS-PAGE sample buffer (25 μL) was then added and the samples were incubated for 1h at 37°C, followed by the addition of 25 μl of water and an additional incubation at 37°C for 30 min. Samples were separated by PAGE on a 7% Tris-acetate gel at constant voltage. The gel was dried and exposed to Bio-Max MR film (Eastman Kodak, Rochester, NY) for 3-6 days at -80°C. The incorporation of [¹²⁵I]-IAAP into the ABCG2 band was quantified by estimating the radioactivity of this band using the STORM

MOL #56192

860 phosphor imager system (Molecular Dynamics, Sunnyvale, CA) and ImageQuaNT software (Shukla et al., 2006).

Cytotoxicity Assays

Four-day cytotoxicity assays with sulforhodamine B were performed as previously described (Skehan et al., 1990). The cells were plated in flat-bottomed, 96-well plates (10,000 cells per well for transfected HEK 293 cells and 5,000 cells per well for NCI-H460 parental and MX20 resistant cells) and allowed to attach for 24 hours at 37°C. Compounds at various concentrations were added to the cells and the plates were allowed to incubate for 96 hours at 37°C. The cells were subsequently fixed in 50% trichloroacetic acid and stained with sulforhodamine B solution (0.4% sulforhodamine B in 1% acetic acid). Optical densities were read on a Bio-Rad plate reader at an absorbance of 540 nm. Each concentration was tested in quadruplicate. Combination studies with putative potential ABCG2 inhibitors and topotecan, a known ABCG2 substrate, were performed in wild-type *ABCG2*-transfected and empty vector-transfected cells using this same method. Relative resistance (RR) values were calculated by dividing the IC_{50} of the ABCG2-expressing line by its corresponding parental line.

RESULTS

ABCG2 function and the NCI-60 cell lines

Relative ABCG2 transporter function in 59 of the 60 cell lines of the drug screen was measured by flow cytometry using the pheophorbide A (PhA) assay. Cells were incubated with PhA in the absence of FTC to generate the efflux histogram (solid line) while cells were

MOL #56192

incubated in PhA in the presence of FTC to generate the FTC/Efflux histogram (dashed line) as outlined in the materials and methods (see Figure 1A). The difference between the two histograms has been shown to correlate with levels of cell surface ABCG2 expression (Robey et al., 2004). Figure 1A shows results from two cell lines found to have the highest levels of ABCG2 function among cells in the screen (A549 and NCI-H460), one cell line with moderate function (NCI-H23) and one with nearly undetectable ABCG2 function (OVCAR4).

Figure 1B summarizes the results from 59 of the 60 cell lines, expressed as the difference in mean channel number between the FTC/efflux and the efflux histograms. This difference reflects the degree of ABCG2 transporter-mediated efflux and thus is a measure of relative ABCG2 function in each cell line. Although levels of ABCG2-mediated PhA efflux were relatively low compared to levels observed in drug-selected cell lines, the highest levels of ABCG2 function were found in the NCI-H460, A549, RPMI-8226, NCI-H23, HCC2998, KM12 and SF295 cell lines. Lower levels were found in IGROV1 and LOX-IMVI, and ABCG2 function was nearly undetectable in HL-60, OVCAR4 and SNB-19 cells.

The NCI-60 cell lines represent nine different tumor types, including leukemia, non-small cell lung cancer, colon cancer, central nervous system tumors, melanoma, ovarian carcinoma, renal cancer, prostate cancer and breast cancer. Relative ABCG2 function by tissue type within the DTP cell lines is shown in Figure 1C. With the exception of four cell lines among the leukemia (RPMI-8226) and lung cancer subsets (A549, NCI-H460, and NCI-H23), the range of ABCG2 function was low across all tumor types.

Correlation Between Expression and Function

MOL #56192

Various measures of *ABCG2* mRNA available from the NCI Molecular Targets Database were used to determine a correlation between expression and ABCG2 function (MT2888). *ABCG2* mRNA expression was analyzed by RT-PCR (MT2678) as well as in gene expression arrays, including the Affymetrix U95 (GC36729, GC56458, and GC93477), the Affymetrix U133 (GC152721 and GC228107), and a customized oligonucleotide expression array (GC14733). We constructed a correlation matrix to determine the relationships between ABCG2 function, ABCG2 mRNA expression and ABCG2 expression determined by the gene expression arrays (Supplemental table 1). Pearson correlation coefficients between functional data and expression data ranged from 0.42 (GC14733) to 0.89 (GC228107), suggesting consensus between arrays and the functional data, except for the Affymetrix U95 A chip, GC94377. Consensus with the latter and any of the other variables was low (correlation coefficient of -0.05 to 0.14), but data from this chip is generally considered unreliable.

Single-nucleotide polymorphisms in the NCI-60 cell lines

As SNP variants are known to impair ABCG2 expression and function, cells expressing these variants may confound results based on mRNA expression. Thus, we evaluated *ABCG2* genotypes in the 60 cell lines of the drug screen. DNA from the NCI-60 cell lines was genotyped to identify the presence of the Q141K allelic variant, previously shown to have diminished function compared to wild-type ABCG2 (Imai et al., 2002; Morisaki et al., 2005), as well as a SNP variant in the first intron of the gene recently found to correlate with chemotherapy toxicity in vivo (Rudin et al., 2008). An additional six variant sites were also genotyped (Table 1). For the Q141K SNP, thirteen cell lines were found to contain a variant allele. Two lines were homozygous for this variant (LOX IMVI and A498). The other eleven

MOL #56192

lines were heterozygous, containing one Q141K variant allele (A549, COLO205, HCT116, SF295, MALME-3M, SK-OV-3, CAKI-1, HOP62, HOP92, UACC-257, and MDA-MB-231).

Twenty-one cell lines contained the intron one variant. Four cell lines were homozygous variant (SW620, OVCAR 5, BT549, and T47D), while seventeen were heterozygous variant (MOLT4, HOP-92, HCC-2998, SF539, SNB19, SNB75, U251, SKMEL2, SKMEL5, OVCAR3, OVCAR8, 786-0, RXF393, TK10, NCI ADR-RES, MDA-MB-231, and HS578T). For the other six variant sites, all 60 cell lines were homozygous wild-type at each SNP site.

To determine whether these variants affected the correlation between gene expression and transporter function, the scatter plot analysis comparing expression with function was repeated after excluding those cell lines with the Q141K SNP or the intron one SNP. There was no clear pattern of improvement in correlation across these measures of gene expression and ABCG2 function (data not shown).

COMPARE analysis

We next used the COMPARE program to probe the drug sensitivity database using the ABCG2 function profile. Since higher ABCG2 expression or function should lead to higher cellular resistance to compounds effluxed by the drug transporter, we hypothesized that our profile of ABCG2 levels across the 60 cell lines could be correlated with the cytotoxicity profiles of substrate drugs, just as was observed for P-glycoprotein (Alvarez et al., 1998; Lee et al., 1997). The COMPARE correlation analysis produces a Pearson correlation coefficient (PCC) correlating ABCG2 levels with the sensitivities of the 60 cell lines to the compounds in the database.

MOL #56192

In the COMPARE program, search parameters can be adjusted, including the requirement for a minimum number of cell lines that correlate with the probe and a minimum standard deviation. Through repeated testing and comparing the fingerprints of identified agents, we determined that optimized settings were: 30 cell lines and standard deviation >0.1 . Since the majority of cell lines had modest and similar functional measures, we chose the lower setting of 30 cell lines (out of 60) with which the ABCG2 fingerprint and a compound had to correlate in order to give a positive result. The standard deviation of >0.1 ensured that compounds had a significant variation across the 60 cell lines, and that a high PCC value showing correlation between the compound and ABCG2 function was not driven by a single or a few cell lines.

We probed the drug sensitivity database using the profile produced by the ABCG2 functional data to identify compounds with a high positive or negative correlation. The PCC is highly positively correlated with values approaching 1.0 and highly negatively correlated with values approaching -1.0. Values that range between -0.3 and +0.3 are thought to be not significantly correlated in the screen. The right panel of Figure 2 shows the ABCG2 fingerprint generated by measuring FTC-inhibitable efflux in the cell lines. This fingerprint was used as the seed in the COMPARE algorithm.

From the NCI DTP web-accessible database, we obtained the cytotoxicity profiles of 175 commonly used chemotherapy agents whose mechanisms are well understood, included as the NCI Anticancer Drug Screen's Standard Agents Database. This profile includes the GI_{50} of a compound for each of the 60 cell lines. Using COMPARE, we related the cytotoxicity profile for each standard agent to ABCG2 function in each cell line using the Pearson's correlation coefficient as well as the Spearman's rank correlation coefficient. There was no significant correlation between the ABCG2 functional fingerprint and the cytotoxicity profiles.

MOL #56192

Surprisingly, as seen in Figure 3, compounds known to be ABCG2 substrates such as mitoxantrone and topotecan had lower than expected correlations of 0.082 and 0.011, respectively. The few exceptions to the generally low PCC values were a significant positive correlation with the agent pancratistatin (PCC=0.447) and a negative correlation with ftorafur (PCC= -0.437). Reanalysis omitting cell lines known to express high levels of P-gp or MRP1 did not improve PCCs (data not shown).

The ABCG2 functional fingerprint was then used as a probe in the larger collection of more than 100,000 synthetic agents that have been studied in the NCI 60. The compounds vary in terms of how well they are characterized, both molecularly and as potential anticancer agents. With this larger collection, only 187 compounds were found to have a positive correlation greater than 0.4 or a negative correlation less than -0.4. One compound (NSC 651644) was found to have a PCC value above 0.6, four compounds had values above 0.5 (NSC 722812, 686342, 625546, and 114609), with 66 compounds having correlations measuring between 0.4 and 0.5 (Table 2). A positive correlation in this setting could indicate that these compounds were ABCG2 substrates. The fingerprint of one compound with a positive PCC (0.456), NSC107392, is shown in the left panel of Figure 2.

Also found from this COMPARE analysis were compounds with negative correlations. Among the compounds found to have a high negative correlation with the ABCG2 functional fingerprint was NSC 651424 (PCC = -0.739). Two additional compounds had correlations between -0.7 and -0.6, and another twenty-three compounds had PCC values between -0.6 and -0.5 (Table 2). Negative correlation in this context suggests that these agents are preferentially toxic to cells that express ABCG2 and could be considered as potential ABCG2 “targeting” agents. This was found to be true in the case of P-gp, where some compounds with negative

MOL #56192

PCCs were found to be more toxic to cells overexpressing the transporter (Alvarez et al., 1995; Szakacs et al., 2004).

Available compounds with high positive and low negative PCCs were obtained from the NCI DTP and subjected to further testing. One limitation at this step was that many compounds with high correlations were not available, including NSC 651424 (PCC=-0.739), 693023 (-0.663), and 671546 (-0.626). A total of 27 compounds were obtained; 17 with positive PCCs and 10 with negative PCCs (Table 3). We selected available compounds with a PCC ≥ 0.4 or ≤ -0.4 as these compounds generally had p-values < 0.005 . Compounds with PCCs ≤ 0.35 tended to have p-values greater than 0.05. In the case of some compounds, the PCC values shown represent the average PCC from several experiments in the drug screen.

Characterization of 27 compounds obtained by COMPARE analysis

To determine whether any of the compounds were substrates of the ABCG2 transporter, 4-day cytotoxicity assays were performed with the 27 compounds on HEK293 cells transfected with empty pcDNA3.1 vector or vector containing DNA encoding the wild-type ABCG2 transporter. Relative resistance values were calculated by dividing the IC_{50} for each compound in the ABCG2-transfected cells by the IC_{50} for each compound in the empty vector-transfected cells. In cytotoxicity assays, ABCG2-expressing HEK cells will be more resistant to a substrate than cells transfected with empty vector, resulting in a higher relative resistance value. ABCG2-expressing HEK cells were 19-fold resistant to topotecan compared to empty vector-transfected cells (Table 3). Substrates, identified as those compounds where there was a greater than 2-fold relative resistance value, included five of the 27 compounds tested (NSC 651644, 107392, 265473, 305458, 349156, and 382054) as listed in Table 3. ABCG2-transfected cells were

MOL #56192

particularly resistant to compounds NSC 107392 (5-hydroxypicolinaldehyde thiosemicarbazone), 265473 ((E)-N-(1-decylsulfanyl-3-hydroxypropan-2-yl)-3-(6-methyl-2,4-dioxo-1H-pyrimidin-5-yl)prop-2-enamide) and 349156 (pancratistatin), with relative resistance values greater than 37-fold, suggesting that these compounds are readily transported by ABCG2. During the course of our study, we discovered that NSC 265473 and 305458 were actually the same compound, providing a serendipitous internal control.

We next sought to determine whether resistance to the test compounds could be conferred by the lower endogenous levels of ABCG2 found in the unselected drug screen cell lines. Four-day cytotoxicity assays were performed on A549, NCI-H460, and HT29 cells with SN-38, topotecan, NSC 107392 or 265473 in the presence or absence of 5 μ M of the ABCG2 inhibitor FTC. Dose modifying factors (DMFs), representing sensitization due to incubation in the presence of FTC, were then calculated by dividing IC_{50} values obtained in the absence of FTC by IC_{50} values obtained in the presence of FTC. In general, DMF values were lower for SN-38 (range 1 to 2.7) and topotecan (range 1 to 2.6) than for the two novel substrates NSC 107392 (range 1.4 to 3.0) and 265473 (range 2.1 to 6.5). However, these differences did not achieve statistical significance.

The negatively correlating compounds were expected to be more toxic to cells expressing ABCG2. However, only two of the 27 tested compounds (NSC 103054 and 174939) showed evidence of greater cytotoxicity in ABCG2 expressing cells with relative resistance values less than 0.5. Unexpectedly, one of two compounds (NSC 103054) that was more toxic to ABCG2-transfected cells had a positive PCC (PCC=0.471). Four of the ten compounds with negative PCCs were not toxic to either of the two transfected cell lines at concentrations of up to 100 μ M.

MOL #56192

We also performed cytotoxicity assays with a subset of the 27 compounds on parental NCI-H460 and ABCG2-overexpressing NCI-H460 MX20 cells. As seen in supplemental table 2, similar relative resistance values were observed and did not differ from those for the transfected cells (Table 3) by more than 3-fold except in the case of 349156 where the transfected cells had relative resistance values that were more than 4-fold higher than for the NCI-H460 and NCI-H460 MX20 cells.

Next, we sought to determine whether these 27 compounds were able to interact with ABCG2 by testing their ability to inhibit photo-crosslinking of ABCG2 with [¹²⁵I]-IAAP as described above. This method has been used to identify compounds that bind to ABCG2 at the same site as prazosin, a known ABCG2 substrate, by measuring their ability to prevent binding of the radiolabeled, photocrosslinkable analog of prazosin, [¹²⁵I]-IAAP, to ABCG2. An example of the gel results from this assay is shown in Figure 4A. Results for each compound are listed in Table 3, with results reported as the percent inhibition of ABCG2 labeling (i.e. 80% inhibited for FTC). Eight of the 17 compounds with a positive PCC inhibited IAAP binding by more than 50% (NSC 651644, 103054, 623636, 620515, 691417, 620303, 297093, and 265473). In addition, five of ten compounds with a negative PCC inhibited IAAP binding by more than 50% (NSC 153330, 45384, 24048, 382054, and 608001).

As another measure of interaction with ABCG2, positively or negatively correlating agents were tested for their ability to inhibit ABCG2 function by determining the effect of 10 μM concentrations of the compounds on the efflux of PhA from wild-type *ABCG2*-transfected cells. *ABCG2*-transfected cells were incubated in PhA in the presence (dashed line) or absence (solid line) of 10 μM each compound, and the fold-increase in PhA fluorescence in the dashed histogram compared to the solid histogram was calculated. Results obtained with 5 of the tested

MOL #56192

compounds and the positive control FTC are given in Figure 4B while results for all compounds are summarized in Table 3. Three of 10 compounds tested with a negative PCC were found to increase PhA fluorescence by 2-fold or more (NSC 24048, 45384, and 608001). In addition, three of 17 compounds with a positive correlation were found to increase intracellular PhA fluorescence by 2-fold or greater (NSC 636795, 103054, and 691417). Structures for selected test compounds are provided in Figure 4C. Structures of other compounds can be obtained from <http://dtp.nci.nih.gov>.

Of the 6 compounds that were able to increase PhA fluorescence in the *ABCG2*-transfected cells at least 2-fold, four compounds that were non-toxic at concentrations shown to inhibit *ABCG2* function were further tested in combination studies with topotecan, a cytotoxic agent known to be a *ABCG2* substrate. Cytotoxicity assays were performed on *ABCG2*-transfected and empty vector-transfected HEK293 cells with topotecan at various concentrations along with non-toxic concentrations of the compounds NSC 608001 (10 μ M, PCC= -0.409), 636795 (10 μ M, PCC=0.477), 153330 (25 μ M, PCC= -0.502), and 24048 (10 μ M, PCC= -0.472). In all cases, the concentrations chosen resulted in less than 10% cell death of both the empty vector-transfected and the *ABCG2*-transfected cells. While NSC608001, 636795, and 153330 partially reversed *ABCG2*-mediated topotecan resistance in *ABCG2*-transfected cells, NSC 24048 completely reversed *ABCG2*-mediated resistance (Table 4).

DISCUSSION

The National Cancer Institute Anticancer Drug Screen has proven to be a powerful basic and translational research tool to identify new anticancer agents, characterize cytotoxic drug activity, and investigate mechanisms of cancer drug resistance. We and others have previously used this research tool and database to identify agents that targeted the epidermal growth factor

MOL #56192

receptor (Liu et al., 2007; Wosikowski et al., 1997), the erbB2 pathway (Wosikowski et al., 1997) and Chk2 (Jobson et al., 2007), as well as agents that were substrates of the drug transporters P-gp (Lee et al., 1994) and MRP1 (Alvarez et al., 1998).

In the current study, we characterized the function of the ABCG2 efflux transporter across the 60 cell lines of the NCI Anticancer Drug Screen. Our hypothesis was that a measure of transporter function may be more sensitive than gene expression to identify compounds interactive with ABCG2, a strategy that in the past has been used successfully to identify substrates for other ABC transporters. Using *ABCG2* gene expression measured by real-time RT-PCR as a fingerprint probe, Szakacs et al. (Szakacs et al., 2004) did not identify transporter substrates within the drug screen. As shown here, using transporter function as a fingerprint to probe the screen did identify novel substrates and inhibitors of this critical drug transporter.

While we did identify potential substrates and targeting agents using transporter function as the seed probe entered into the COMPARE program, in general we were unable to identify as many compounds as were identified previously when P-glycoprotein function was used as the seed (Lee et al., 1994). Using PhA efflux as a measure of ABCG2 function, only one compound was found to have a PCC value above 0.6, only four compounds had values above 0.5, and with 66 compounds measuring between 0.4 and 0.5. While these values are low compared to correlations obtained using P-gp function as the seed, where PCC values for the top 20 compounds ranged from 0.816 to 0.976, they are in the same range as that observed for several molecular targets, including MRP1 (Alvarez et al., 1998) and EGFR (Wosikowski et al., 1997). Surprisingly, known substrates of ABCG2 that are found in the drug screen such as mitoxantrone, topotecan, and SN-38 (the active metabolite of irinotecan), were not found to significantly correlate with ABCG2 function, leading us to the conclusion that the screen cannot

MOL #56192

be used as a predictive tool to determine whether or not a compound is a substrate. We were, however, able to identify the novel ABCG2 substrates NSC 107392 (5-hydroxypicolinaldehyde thiosemicarbazone), 265473 ((E)-N-(1-decylsulfanyl-3-hydroxypropan-2-yl)-3-(6-methyl-2,4-dioxo-1H-pyrimidin-5-yl)prop-2-enamide) and 349156 (pancratistatin). Pancratistatin is under investigation for its antitumor properties (McLachlan et al., 2005). Interestingly, a previously reported P-gp targeting agent, a thiosemicarbazone, was also shown to be an ABCG2 substrate (Wu et al., 2007).

Several possibilities may explain the somewhat low PCC values obtained and why known substrates were not identified. First, the range of ABCG2 function across the cell lines in the screen is not as broad as that for P-gp. When values are widely separated across the 60 cell lines, stronger correlations are possible. Few cell lines have relatively high function of ABCG2 as measured by PhA efflux (A549, NCI-H460, RPMI 8226, and NCI-H23). This compares to 12 cell lines found to have high P-gp function in our previous work, some at levels found in drug-selected cell lines (Lee et al., 1994). The generally low levels of ABCG2 expression in the cell lines of the drug screen would also serve to reduce correlations for compounds that are relatively poor substrates of ABCG2 such as flavopiridol, since high levels of ABCG2 expression are needed to confer resistance to such compounds. Ultimately, including more cell lines with higher levels of ABCG2 in the drug screen might allow for identification of known ABCG2 substrates. Second, the contribution of the drug target might obscure the contribution of ABCG2 to resistance. Cancer cells that express high levels of a drug target, such as topoisomerase, may be exquisitely sensitive to drugs targeting the protein such that ABCG2 is not able to keep intracellular drug concentrations low enough to confer resistance. Similarly, ABCG2 substrates such as imatinib would not be identified as substrates by the drug screen unless cell lines

MOL #56192

expressed the BCR-ABL fusion protein or an activating KIT mutation. Third, expression of other transporters, such as P-gp or MRP1, may obscure the contribution of ABCG2 to drug resistance in a given cell line. Some in vitro studies support such a hypothesis, since, for example, topotecan uptake into the brain was not observed to be increased in *Abcg2*-deficient mice until the *Mdr1/2* genes were also deleted (de Vries et al., 2007). Another possibility is that SNPs may directly affect ABCG2 function. A polymorphism that impairs function could readily explain the failure of gene expression data to correlate with cytotoxicity data. However, a functional measure should account for any influence of polymorphic forms of ABCG2 as we presently understand them. Further, our analyses on the correlation between function and expression, as well as the correlation between compound cytotoxicity and function, did not improve when genetic variant cell lines were excluded. Finally, ABCG2 localization may have an impact on drug resistance. Intracellular expression of ABCG2 has been observed in some tissue samples and it is unknown whether intracellular ABCG2 can mediate drug resistance. If so, measuring PhA efflux might underestimate the contribution of ABCG2 to drug-resistance in some cell lines. If this were true, measurement of ABCG2 by immunoblot should improve correlations, but, again, levels of ABCG2 remain generally low in the 60 cell lines of the screen. Nonetheless, measurement of ABCG2 function did allow us to identify novel compounds that interact with ABCG2.

In this analysis we also looked for correlations with PCC values that were negative in order to identify compounds that might target cells that express high levels of ABCG2. Of the 27 compounds that we examined, only two were slightly more toxic (2.5-fold and 3-fold) in ABCG2-transfected cells versus empty vector transfected cells. As the COMPARE program was able to identify compounds with negative PCCs that selectively target cells that overexpress P-gp

MOL #56192

(Szakacs et al., 2004), it is possible that similar compounds that are selectively toxic to ABCG2-overexpressing cells could be identified.

ABCG2-targeting compounds may be of interest for a novel clinical approach--that of targeting putative cancer stem cells. Normal hematopoietic stem cells as well as cancer stem cells are identified by flow cytometry in a distinct population of cells that stain dimly with the fluorescent dye, Hoechst 33342. This so-called "side population" is due to ABCG2-mediated Hoechst efflux and is enriched in tumorigenic or potential cancer stem cells (Zhou et al., 2001). Whether true cancer stem cells exist or not is still hotly debated, but it does appear that cells in this side population could have intrinsic chemotherapy resistance due to ABCG2-mediated drug efflux. Therefore, a potential therapeutic modality would be to use compounds that are selectively toxic to this subset of cells.

Of the 27 compounds tested, six were found to inhibit ABCG2-mediated PhA transport in ABCG2 transfected cells at 10 μ M. In particular, NSC 24048, 15330, 608001 and 636795 were sufficiently non-toxic so that combination cytotoxicity assays could be performed. Interestingly, these included compounds with both positive and negative PCCs. NSC 24048 was the most potent compound tested and completely reversed ABCG2-mediated topotecan resistance in the ABCG2-transfected cells at a concentration of 10 μ M. The identification of potential inhibitors of the ABCG2 drug transporter may prove to be clinically useful given the central role that ABCG2 plays in the blood-brain barrier and in mediating oral absorption of drugs. ABCG2 inhibitors may provide increased delivery of chemotherapy agents into sanctuary sites such as the brain in order to treat primary or metastatic disease (Breedveld et al., 2005).

In conclusion, measurements of ABCG2 transporter function were more successful than gene expression when used as a probe to identify drugs that interact with this transporter. We

MOL #56192

identified novel cytotoxic agents that are substrates of ABCG2, as well as some drugs that functioned as transport inhibitors. Further investigations and preclinical evaluation of these substrates and inhibitors are warranted, and are ongoing.

MOL #56192

REFERENCES

- Alvarez M, Paull K, Monks A, Hose C, Lee JS, Weinstein J, Grever MR, Bates SE and Fojo AT (1995) Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the NCI anticancer drug screen. *J Clin Invest* **95**:2205-2214.
- Alvarez M, Robey R, Sandor V, Nishiyama K, Matsumoto Y, Paull K, Bates S and Fojo T (1998) Using the national cancer institute anticancer drug screen to assess the effect of MRP expression on drug sensitivity profiles. *Mol Pharmacol* **54**(5):802-814.
- Benderra Z, Faussat AM, Sayada L, Perrot JY, Chaoui D, Marie JP and Legrand O (2004) Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. *Clin Cancer Res* **10**(23):7896-7902.
- Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH and Schellens JH (2005) The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. *Cancer Res* **65**(7):2577-2582.
- de Bruin M, Miyake K, Litman T, Robey R and Bates SE (1999) Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. *Cancer Lett* **146**(2):117-126.
- de Vries NA, Zhao J, Kroon E, Buckle T, Beijnen JH and van Tellingen O (2007) P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. *Clin Cancer Res* **13**(21):6440-6449.
- Deeken JF and Loscher W (2007) The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. *Clin Cancer Res* **13**(6):1663-1674.
- Dumauld C, Miao X, Daly T, Bruckner C, Njau R, Fu D, Close-Kirkwood S, Bauer N, Watanabe N, Hardenbol P and Hockett R (2007) Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix Targeted Genotyping System. *Pharmacogenomics* **8**(3):293-305.
- Fetsch PA, Abati A, Litman T, Morisaki K, Honjo Y, Mittal K and Bates SE (2005) Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues. *Cancer Lett.*
- Hardwick LJ, Velamakanni S and van Veen HW (2007) The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2). *Br J Pharmacol* **151**(2):163-174.
- Honjo Y, Morisaki K, Huff LM, Robey RW, Hung J, Dean M and Bates SE (2002) Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR/BCRP/ABCP1). *Cancer Biol Ther* **1**(6):696-702.
- Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, Tsuruo T, Miki Y and Sugimoto Y (2002) C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. *Mol Cancer Ther* **1**(8):611-616.
- Jobson AG, Cardellina JH, 2nd, Scudiero D, Kondapaka S, Zhang H, Kim H, Shoemaker R and Pommier Y (2007) Identification of a Bis-guanylhydrazone [4,4'-Diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Chk2 kinase. *Mol Pharmacol* **72**(4):876-884.
- Lee JK, Bussey KJ, Gwadyr FG, Reinhold W, Riddick G, Pelletier SL, Nishizuka S, Szakacs G, Annereau JP, Shankavaram U, Lababidi S, Smith LH, Gottesman MM and Weinstein JN

MOL #56192

- (2003) Comparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cells. *Genome Biol* **4**(12):R82.
- Lee JS, Paull K, Alvarez M, Hose C, Monks A, Grever M, Fojo AT and Bates SE (1994) Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute Drug Screen. *Mol Pharmacol* **46**:627-638.
- Lee JS, Scala S, Matsumoto Y, Dickstein B, Robey R, Zhan Z, Altenberg G and Bates SE (1997) Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression. *J Cell Biochem* **65**(4):513-526.
- Lepper ER, Nooter K, Verweij J, Acharya MR, Figg WD and Sparreboom A (2005) Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. *Pharmacogenomics* **6**(2):115-138.
- Liu W, Wu X, Zhang W, Montenegro RC, Fackenthal DL, Spitz JA, Huff LM, Innocenti F, Das S, Cook EH, Jr., Cox NJ, Bates SE and Ratain MJ (2007) Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. *Clin Cancer Res* **13**(22 Pt 1):6788-6795.
- Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ and Schellens JH (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. *Cancer Res* **61**(8):3458-3464.
- McLachlan A, Kekre N, McNulty J and Pandey S (2005) Pancratistatin: a natural anti-cancer compound that targets mitochondria specifically in cancer cells to induce apoptosis. *Apoptosis* **10**(3):619-630.
- Minderman H, O'Loughlin KL, Pendyala L and Baer MR (2004) VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. *Clin Cancer Res* **10**(5):1826-1834.
- Mizuarai S, Aozasa N and Kotani H (2004) Single nucleotide polymorphisms result in impaired membrane localization and reduced ATPase activity in multidrug transporter ABCG2. *Int J Cancer* **109**(2):238-246.
- Morisaki K, Robey RW, Ozvegy-Laczka C, Honjo Y, Polgar O, Steadman K, Sarkadi B and Bates SE (2005) Single nucleotide polymorphisms modify the transporter activity of ABCG2. *Cancer Chemother Pharmacol* **56**(2):161-172.
- O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJJ and Kohn KW (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. *Cancer Res* **57**(19):4285-4300.
- Rabindran SK, He H, Singh M, Brown E, Collins KI, Annable T and Greenberger LM (1998) Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. *Cancer Res* **58**(24):5850-5858.
- Robey RW, Honjo Y, Morisaki K, Nadjem TA, Runge S, Risbood M, Poruchynsky MS and Bates SE (2003) Mutations at amino acid 482 in the ABCG2 gene affect substrate and antagonist specificity. *Br J Cancer* **89**:1971-1978.
- Robey RW, Medina-Perez WY, Nishiyama K, Lahusen T, Miyake K, Litman T, Senderowicz AM, Ross DD and Bates SE (2001) Overexpression of the ATP-binding cassette half-

MOL #56192

- transporter, ABCG2 (MXR/BCRP/ABCP1), in flavopiridol-resistant human breast cancer cells. *Clin Cancer Res* **7**(1):145-152.
- Robey RW, Polgar O, Deeken J, To KW and Bates SE (2007) ABCG2: determining its relevance in clinical drug resistance. *Cancer Metastasis Rev* **26**(1):39-57.
- Robey RW, Steadman K, Polgar O, Morisaki K, Blayney M, Mistry P and Bates SE (2004) Pheophorbide a is a specific probe for ABCG2 function and inhibition. *Cancer Res* **64**(4):1242-1246.
- Rudin CM, Liu W, Desai A, Karrison T, Jiang X, Janisch L, Das S, Ramirez J, Poonkuzhali B, Schuetz E, Fackenthal DL, Chen P, Armstrong DK, Brahmer JR, Fleming GF, Vokes EE, Carducci MA and Ratain MJ (2008) Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. *J Clin Oncol* **26**(7):1119-1127.
- Shukla S, Robey RW, Bates SE and Ambudkar SV (2006) The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. *Biochemistry* **45**(29):8940-8951.
- Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. *J Natl Cancer Inst* **82**(13):1107-1112.
- Suvannasankha A, Minderman H, O'Loughlin KL, Nakanishi T, Ford LA, Greco WR, Wetzler M, Ross DD and Baer MR (2004) Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival. *Br J Haematol* **127**(4):392-398.
- Szakacs G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, Bussey KJ, Reinhold W, Guo Y, Kruh GD, Reimers M, Weinstein JN and Gottesman MM (2004) Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. *Cancer Cell* **6**(2):129-137.
- Wosikowski K, Schuurhuis D, Johnson K, Paull KD, Myers TG, Weinstein JN and Bates SE (1997) Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns. *J Natl Cancer Inst* **89**(20):1505-1515.
- Wu C, Shukla S, Calcagno A, Hall M, Gottesman M and Ambudkar S (2007) Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter. *Mol Cancer Ther* **6**(12 Pt 1):3287-3296.
- Zamber CP, Lamba JK, Yasuda K, Farnum J, Thummel K, Schuetz JD and Schuetz EG (2003) Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. *Pharmacogenetics* **13**(1):19-28.
- Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H and Sorrentino BP (2001) The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. *Nat Med* **7**(9):1028-1034.

MOL #56192

Footnotes

This work was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research, Bethesda, MD, USA.

This work was supported in part by the National Institutes of Health/National Institute of General Medical Sciences Pharmacogenetics Research Network and Database [(U01GM61374, <http://pharmgkb.org>) under grant U01 GM61393], the National Institutes of Health Cancer Center Support grant [P30 CA21765], and by the American Lebanese Syrian Associated Charities (ALSAC).

The content of this paper does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U. S. Government.

Requests for reprints: John Deeken, M.D. Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Road, N.W., Washington, D.C. 20007, USA; E-mail: deekenj@georgetown.edu; Tel: +1 (202) 444-3959; Fax: +1 (202) 444-9429.

MOL #56192

Figure legends

Figure 1: Pheophorbide a efflux in cell lines from the NCI Anticancer Drug Screen. A. Cells were trypsinized and incubated in 1 μ M PhA in the presence or absence of 10 μ M of the ABCG2 inhibitor FTC for 30 min. Cells were then washed and allowed to incubate for 1 h in PhA-free medium continuing with (dashed line) or without (solid line) FTC and intracellular fluorescence of PhA was determined. Representative results from one of at least three experiments with A549, H460, NCI-H23 and OVCAR 4 cells are shown. B. ABCG2 function in the 60 cell lines of the NCI Anticancer Drug Screen was measured using pheophorbide a (PhA) as outlined in (A) above and the difference in mean channel number between the dashed and solid histograms was calculated to obtain a measure of ABCG2-mediated efflux. Bars represent average efflux values from at least 3 independent experiments for each cell line. C. Average efflux values obtained as outlined in (B) above were plotted versus tumor type.

Figure 2: Comparison of the mean graph (fingerprint) of ABCG2 function with the GI₅₀ mean graph (fingerprint) of NSC 107392 (PCC 0.456) across the NCI 60 cell lines. *ABCG2 Function*: the vertical line represents the mean value across the 60 cell lines. The horizontal bars reflect the deviation from this mean for each cell line. Bars pointing to the left of the mean line are from cell lines with transporter function greater than the mean, while bars pointing to the right are from cell lines with ABCG2 function less than the mean. *NSC107392*: in the mean graph (fingerprint) from this compound found to be a substrate for ABCG2, the vertical line represents the GI₅₀ across all 60 cell lines. Bars pointing to the left represent cell lines requiring concentrations higher than the mean to kill 50% of the cells from time 0. Thus, cell lines with bars pointing to the left are more resistant to this ABCG2 substrate. Bars pointing to the right

MOL #56192

reflect cell lines that are more sensitive to the drug. It should be noted that the U251 and SNB-19 cell lines are reported to be from the same individual; the MDA-MB-435 cell line, listed as a breast cancer line, is suggested to be a melanoma; and the NCI/ADR-RES was determined to be derived from the OVCAR-8 cell line despite it being listed as a breast cancer by the drug screen.

Figure 3: Correlation between ABCG2 function and standard agents in NCI Anticancer Drug Screen. Pearson correlation coefficient (PCC) values are shown between the ABCG2 function fingerprint and the cytotoxicity profiles of 170 commonly used standard chemotherapy agents.

Figure 4: Interaction of compounds identified by the NCI-ADS with ABCG2. A. Crude membranes isolated from MCF-7 FLV1000 cells were incubated with 20 μ M of the compounds in the presence of [125 I]-IAAP followed by UV crosslinking and immunoprecipitation of ABCG2 as outlined in the methods section. An autoradiogram from a representative experiment is shown. Membranes were also incubated with 20 μ M FTC as a positive control for inhibition of labeling of ABCG2 by [125 I]-IAAP. B. Inhibition of PhA efflux was measured in wild-type ABCG2-transfected cells by incubating cells in 1 μ M PhA in the presence or absence of 10 μ M of the compounds identified by COMPARE analysis for 30 min. Subsequently, cells were washed and allowed to incubate in PhA-free medium for 1 h continuing with (dashed line) or without (solid line) 10 μ M of the compounds. Representative histograms from one of at least two experiments is shown. Cells incubated in 10 μ M FTC serve as a positive control for inhibition of ABCG2-mediated PhA transport. C. Chemical structures of selected ABCG2-interacting compounds.

MOL #56192

Table 1. ABCG2 Genetic Variants in the NCI60 Cell Lines

Nucleotide Change	Amino Acid	Reference Sequence	Cell Lines	
			Heterozygote Variants	Homozygote Variants
	Intron 1	rs2622604	MOLT4, HOP-92, HCC2998, SF539, SNB19, SNB75, U251, SKMEL2, SKMEL5, OVCAR3, OVCAR8, RXF393, TK10, NCI ADR-RES, MDA-MB-231, HS578T, 786-0	SW620, OVCAR 5, BT549, T47D
914C>A	Q141K	rs2231142	A549, COLO205, HCT116, SF295, MALME-3M, SK-OV-3, CAKI-1, HOP62, HOP92, UACC-257, MDA-MB-231	LOX IMVI, A498
862C>T	Y123Y	rs2231139	None	None
989C>G	Q166E	rs1061017	None	None
1057A>G	G188G	rs3116439	None	None
1116T>C	F208S	rs1061018	None	None
1235T>C	S248P	rs3116448	None	None
1493G>T	E334*	rs3201997	None	None

Genotyping of *ABCG2* was performed as described in the materials and methods section.

MOL #56192

Table 2. Compounds identified by the COMPARE algorithm as correlating with ABCG2 function

Potential Substrates				Potential Targeting Agents			
Rank	Compound	PCC	Name	Rank	Compound	PCC	Name
1	651644	0.635		1	651424	-0.739	
2	722812	0.592		2	723121	-0.616	
3	686342	0.516		3	716430	-0.611	
4	625546	0.506	Cordigone	4	674449	-0.587	
5	114609	0.503		5	679209	-0.572	
6	696102	0.492		6	668352	-0.571	
7	736740	0.489		7	624663	-0.570	Betulitrin
8	626879	0.479		8	697538	-0.568	
9	668355	0.478		9	141539	-0.562	
10	636795	0.477		10	672223	-0.551	
11	717452	0.476		11	702426	-0.550	
12	665697	0.476		12	652295	-0.545	
13	622161	0.471		13	679280	-0.540	
14	103054	0.471	2,4-Dibromoestradiol	14	664904	-0.538	
15	305458	0.468		15	661963	-0.538	
16	715406	0.464		16	668351	-0.530	
17	623636	0.464		17	601348	-0.529	
18	620515	0.463		18	660031	-0.522	
19	652903	0.462	Saframycin	19	691529	-0.520	
20	630986	0.458		20	691209	-0.519	
21	621888	0.458		26	153330	-0.502	
22	655897	0.457		29	45384	-0.498	ME-Streptonigrin
23	107392	0.456	5-HP	30	58368	-0.497	Fumagillin
24	174137	0.456		42	24048	-0.472	
25	175150	0.455	Rosamicin	47	69574	-0.466	
26	349156	0.447	Pancreatistatin	48	382054	-0.465	
27	691417	0.440		70	600391	-0.439	
28	620303	0.438		81	148958	-0.431	Tegafur
29	691782	0.438		104	608001	-0.409	
32	313981	0.436					
36	297093	0.430					
72	274557	0.400					
74	265473	0.399					

Compounds whose cytotoxicity profile or 'fingerprint' across the NCI 60 cell lines have the highest positive and negative correlations with the ABCG2 functional results are listed, including the value of the Pearson Correlation Coefficient.

MOL #56192

Table 3. Summary of test data for compounds identified as correlating with ABCG2 function as measured by PhA transport.

Compound	Pearson Correlation Coefficient	p-value	Relative Resistance ^a	IAAP binding (% Inhibited) ^b	Pheophorbide fluorescence (fold increase) ^c
636795	0.48	6.1x10 ⁻⁴	0.94	15	2.4
103054	0.47	ND	0.33	81	3.1
305458 ^d	0.47	9.1x10 ⁻⁴	38	45	0.99
623636	0.46	3.4x10 ⁻³	1	99	1.1
620515	0.46	ND	1.1	70	1.3
621888	0.46	ND	0.86	0	1.1
107392	0.46	ND	47	30	0.97
174137	0.46	3.2x10 ⁻⁴	0.96	43	0.9
175150	0.46	3.8x10 ⁻⁴	0.8	15	1.2
349156	0.45	3.9x10 ⁻⁴	37	17	0.92
691417	0.44	7.8x10 ⁻⁴	0.92	62	2
620303	0.44	1.8x10 ⁻³	0.86	65	1
691782	0.44	9.1x10 ⁻⁴	1.2	25	1.1
313981	0.44	1.9x10 ⁻³	1.2	30	1.3
297093	0.43	1.8x10 ⁻³	1.5	65	1
274557	0.40	4.8x10 ⁻³	1.2	22	1.8
265473 ^d	0.40	5.4x10 ⁻³	98	79	1
608001	-0.41	ND	0.7	80	2
148958	-0.43	4.8x10 ⁻⁴	non-toxic	25	0.94
600391 ^e	-0.44	5.0x10 ⁻⁴	non-toxic	0	1.2
174939	-0.45	ND	0.4	30	1.2
382054	-0.46	ND	2.4	60	1.2
69574	-0.47	6.5x10 ⁻⁴	0.9	27	1.3
24048	-0.47	2.7x10 ⁻⁴	non-toxic	78	15
58368	-0.50	3.7x10 ⁻⁴	non-toxic	30	1
45384	-0.50	3.7x10 ⁻⁴	1.9	85	12
153330	-0.50	6.1x10 ⁻⁵	0.92	73	1.8

Compounds marked non-toxic were not cytotoxic at concentrations up to 100 μ M. ABCG2-transfected cells were 19-fold resistant to topotecan compared to empty vector-transfected cells. Where p-values were not determined (ND), the PCC represents an average of several PCCs for different experiments with a given compound in the drug screen.

^aRelative resistance was calculated by dividing the IC₅₀ of each compound for the ABCG2-transfected cell line by the IC₅₀ value for the empty vector transfected cell line. Values given are means from at least 2 independent experiments.

^bPercent inhibition of IAAP labeling of ABCG2 was determined after normalizing the value of all bands to the value obtained for IAAP incorporation into the untreated band, which was set to 100%. Values are means from 2 independent experiments

^cFold increase in PhA fluorescence was determined by dividing the intracellular fluorescence of PhA in the presence of 10 μ M inhibitor by the PhA fluorescence in the absence of inhibitor. Values are means from at least 2 independent experiments.

^dThe IC₅₀ value for the ABCG2 expressing line was not achieved, thus, the actual relative resistance value is likely higher.

^eThe molecular weight of this compound is not known. The compound was non-toxic up to a concentration of 100 μ g/ml.


MOL #56192

Table 4. Reversal of ABCG2-mediated topotecan resistance by compounds 24048, 153330, 608001, 636795.


Drug	pcDNA	R-2	RR^a
Topotecan	0.021±0.008	0.39±0.06	19
Topotecan + 10 µM 24048	0.026±0.01	0.019±0.005	0.73
Topotecan + 25 µM 153330	0.018±0.01	0.087±0.03	4.8
Topotecan + 10 µM 608001	0.015±0.001	0.10±0.01	6.7
Topotecan + 10 µM 636795	0.017±0.004	0.083±0.02	4.9

^aRelative resistance values were obtained by dividing the IC₅₀ values in R-2 cells for topotecan in the absence or presence of the desired compound by the IC₅₀ value for the pcDNA cells without compounds added. Values are mean ± standard deviation. At least 3 independent experiments were performed.

A.



B.



C.




Figure 1

NSC 107392

ABCG2 Function




Figure 2




Figure 3

